New hope for Tough-to-Treat lung cancer: trial targets specific mutation
NCT ID NCT07286149
Summary
This study is testing a new targeted drug called MK-1084 for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The main goals are to see if the drug is safe and if it can shrink or get rid of the cancer. The study is for people whose cancer has gotten worse after trying one or two other standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NEOPLASM MALIGNANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clermont Oncology Center ( Site 0041)
RECRUITINGClermont, Florida, 34711, United States
Contact Phone: •••-•••-••••
-
Severance Hospital, Yonsei University Health System ( Site 0080)
RECRUITINGSeoul, 03722, South Korea
Contact Phone: •••-•••-••••
-
Shaare Zedek Medical Center ( Site 0186)
RECRUITINGJerusalem, 9103102, Israel
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.